Richard Harris

Award-winning journalist Richard Harris has reported on a wide range of topics in science, medicine and the environment since he joined NPR in 1986. In early 2014, his focus shifted from an emphasis on climate change and the environment to biomedical research.

Harris has traveled to all seven continents for NPR. His reports have originated from Timbuktu, the South Pole, the Galapagos Islands, Beijing during the SARS epidemic, the center of Greenland, the Amazon rain forest, the foot of Mt. Kilimanjaro (for a story about tuberculosis), and Japan to cover the nuclear aftermath of the 2011 tsunami.

In 2010, Harris' reporting revealed that the blown-out BP oil well in the Gulf of Mexico was spewing out far more oil than asserted in the official estimates. That revelation led the federal government to make a more realistic assessment of the extent of the spill.

Harris covered climate change for decades. He reported from the United Nations climate negotiations, starting with the Earth Summit in Rio de Janeiro in 1992, and including Kyoto in 1997 and Copenhagen in 2009. Harris was a major contributor to NPR's award-winning 2007-2008 "Climate Connections" series.

Over the course of his career, Harris has been the recipient of many prestigious awards. Those include the American Geophysical Union's 2013 Presidential Citation for Science and Society. He shared the 2009 National Academy of Sciences Communication Award and was a finalist again in 2011. In 2002, Harris was elected an honorary member of Sigma Xi, the scientific research society. Harris shared a 1995 Peabody Award for investigative reporting on NPR about the tobacco industry. Since 1988, the American Association for the Advancement of Science has honored Harris three times with its science journalism award.

Before joining NPR, Harris was a science writer for the San Francisco Examiner. From 1981 to 1983, Harris was a staff writer at The Tri-Valley Herald in Livermore, California, covering science, technology, and health issues related to the nuclear weapons lab in Livermore. He started his career as an AAAS Mass Media Science Fellow at the now-defunct Washington Star in DC.

Harris is co-founder of the Washington, DC, Area Science Writers Association, and is past president of the National Association of Science Writers. He serves on the board of the Council for the Advancement of Science Writing.

Harris' book Rigor Mortis was published in 2017. The book covers the biomedicine "reproducibility crisis" — many studies can't be reproduced in other labs, often due to lack of rigor, hence the book's title. Rigor Mortis was a finalist for the 2018 National Academy of Sciences/Keck Communication Award.

A California native, Harris returned to the University of California-Santa Cruz in 2012, to give a commencement address at Crown College, where he had given a valedictory address at his own graduation. He earned a bachelor's degree at the school in biology, with highest honors.

Last month the White House issued guidelines suggesting a way to reduce the number of false positive results in antibody tests: Run two tests. But that strategy has not yet been validated for coronavirus testing. And the details matter.

Most people infected with the novel coronavirus develop antibodies in response.

But scientists don't know whether people who have been exposed to the coronavirus will be immune for life, as is usually the case for the measles, or if the disease will return again and again, like the common cold.

The Food and Drug Administration is stiffening its rules to counteract what some have called a Wild West of antibody testing for the coronavirus.

These tests are designed to identify people who have been previously exposed to the virus. The FDA said more than 250 developers have been bringing products to the market in the past few weeks.

Dozens of blood tests are rapidly coming on the market to identify people who have been exposed to the coronavirus by checking for antibodies against it.

The Food and Drug Administration doesn't set standards for these kinds of tests, but even those that meet the government's informal standard may produce many false answers and provide false assurances. The imperfect results could be a big disappointment to people who are looking toward these tests to help them return to something resembling a normal life.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

In New York today, Democratic Gov. Andrew Cuomo shared this news. For the second day in a row, his state did not see a large rise in COVID-19 deaths.

(SOUNDBITE OF ARCHIVED RECORDING)

The Centers for Disease Control and Prevention has more reassuring news about coronavirus infections among children.

A study published Monday finds that people in the United States under the age of 18 are far less likely to fall ill with COVID-19 or require intensive care, compared with older Americans.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

The nation's 15 days of social distancing are nearly over. And while many states have issued stay-at-home orders for much longer periods of time, new guidance from the White House coronavirus task force is due soon.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

The toll of the coronavirus pandemic is steep - hundreds of thousands of confirmed infections around the world, tens of thousands of lives lost.

ALISA CHANG, HOST:

Post updated 8:15 a.m. March 27, to reflect that the abstract in PubMed has been marked retracted.

When asked why the United States didn't import coronavirus tests when the Centers for Disease Control and Prevention ran into difficulty developing its own, government officials have frequently questioned the quality of the foreign-made alternatives.

But NPR has learned that the key study they point to was retracted just days after it was published online in early March.

During a news conference Wednesday evening, President Trump said: "We don't have to test the entire state in the Middle West or wherever they may be. We don't have to test the entire state. I think it's ridiculous. A lot of those states could go back [to work] right now, and they probably will."

He's correct that the entire population of a state does not need to be tested right now. However, all 50 states do have cases, and those small- and medium-sized outbreaks may be growing exponentially.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

Tonight, President Trump tried to quell rising fears about the effects of the growing coronavirus outbreak.

(SOUNDBITE OF ARCHIVED RECORDING)

Despite worrisome new outbreaks in Iran, Italy and South Korea, the coronavirus disease called COVID-19 is not currently a pandemic, the World Health Organization said today.

In fact, there are some encouraging trends, especially in Hubei province, where most of the cases have been reported.

The epidemic there appears to have plateaued in late January and is continuing on a good trajectory. Dr. Bruce Aylward led a WHO trip to China with a scientific delegation that just concluded. On Sunday, he told reporters in Beijing that trend is real.

Cancer death rates in the United States took their sharpest drop on record between 2016 and 2017, according to an analysis by the American Cancer Society.

Cancer death rates in the U.S. have been falling gradually for about three decades, typically about 1.5% a year. But during the latest study period, the cancer mortality rate dropped 2.2%, "the biggest single-year drop ever," says Rebecca Siegel, scientific director for surveillance research at the cancer society.

Alexa Kasdan had a cold and a sore throat.

The 40-year-old public policy consultant from Brooklyn, N.Y., didn't want her upcoming vacation trip ruined by strep throat. So after it had lingered for more than a week, she decided to get it checked out.

Kasdan visited her primary care physician, Roya Fathollahi, at Manhattan Specialty Care, just off Park Avenue South and not far from tony Gramercy Park.

The Trump administration's plan to ban most flavored vaping products has stalled out, at least for the moment.

Two months ago, President Trump announced he was pursuing the new policy to put a dent in the youth vaping epidemic. The plan was supposed to have been unveiled in a matter of weeks.

But industry pushback and the politics of vaping appear to have derailed that process.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

When the first cases of vaping-related lung injuries came to the attention of scientists at the Centers for Disease Control and Prevention this summer, they knew this was a potential curveball.

Disease detectives, more accustomed to stopping food-borne illnesses or tracking the annual influenza cycle, realized that they'd need a unique approach to take on a health crisis that has so far sickened 1,604 and killed 34.

Copyright 2019 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

When Alex Yiu was born 14 years ago, he seemed like a typical healthy kid. But when he turned 2, his mother, Caroline Cheung-Yiu, started noticing things that were amiss — first little problems, then much bigger ones.

As Alex's health slowly deteriorated, Caroline and her husband, Bandy Yiu, set off on what has become known among families like theirs as a "diagnostic odyssey." This ended up being a 12-year quest that ended after a lucky accident.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Researchers say they have identified the first clearly effective treatments for Ebola, a deadly disease that continues to spread in central Africa. The experimental drugs will be made widely available in the centers that have already treated thousands of patients.

This achievement is particularly notable given the extraordinary circumstances: Scientists in the Democratic Republic of Congo have been running a study in the midst of a deadly epidemic and in the face of armed assaults on doctors.

How do we grow from a single fertilized egg into a fully grown person with trillions of cells? Our cells divide, of course!

And it's no mean feat. Each time a cell divides, it must duplicate our 23 pairs of chromosomes and make sure each "daughter" cell ends up with a complete set of genes.

Errors are potentially fatal to the cell. Runaway cell division, which is the hallmark of cancer, is also serious business.

No wonder then that biologists have been studying cell division for as long as they've known about cells.

Copyright 2019 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Pages